Celltrion files patent application for new breast cancer drug

Published: 2012-10-18 06:57:00

Updated: 2012-10-18 06:57:00

A local biopharmaceutical company has pushed up with its project to develop an ADR (antibody-drug conjugate) based breast cancer drug, paving the way for it to enter a new market with lucrative potential.

Celltrion announced yesterday that it filed a patent application for CT-P26 after animal ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK